Final Results for 13 months to 31 December 2019
RNS & Investor News
Exercise of Warrants and Issue of Equity
17 June 2015
OptiBiotix Health Plc (AIM: OPTI), a Life Sciences business developing compounds to tackle obesity, high cholesterol and diabetes announces that the Company has received notification from warrant holders to exercise warrants over 7,293 ordinary shares of 2p each in the Company at an exercise price of 8p per share, providing the Company with gross proceeds of £583.
Application will be made to the London Stock Exchange to admit the 7,293 new ordinary shares to trading on AIM. Admission of the new ordinary shares is expected to occur on or around 23 June 2015. The new ordinary shares will rank pari passu with the existing ordinary shares.
For the purpose of the Disclosure and Transparency Rules, following the issue of shares detailed above the enlarged issued share capital of the Company will comprise 73,576,910 ordinary shares of 2p each. The above figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company, under the Disclosure and Transparency Rules.
For further information, please contact:
|OptiBiotix Health Plc
Stephen O'Hara, Chief Executive
Contact via Walbrook below
|Cairn Financial Advisers LLP
Liam Murray / Avi Robinson
|Tel: 020 7148 7900|
Claire Louise Noyce
|Tel: 020 3713 4581|
|Peterhouse Corporate Finance Ltd
Lucy Williams / Duncan Vasey
|Tel: 020 7469 0936|
|Walbrook PR Ltd
|Tel: 020 7933 8780 or [email protected]
Mob: 07876 741 001
Mob: 07900 608 002
About OptiBiotix - www.optibiotix.com
OptiBiotix was formed in March 2012 to develop compounds which modify the human microbiome - the collective genome of the microbes in the body - to prevent and manage human disease.
The aim of OptiBiotix is to discover and develop microbial strains, compounds and formulations, which modulate the human microbiome and can be used as food ingredients and supplements or active compounds for the prevention and management of human metabolic diseases, examples of which include obesity, cholesterol and lipid distribution and diabetes.
OptiBiotix has established a pipeline of microbiome modulators that can impact on lipid and cholesterol management, energy harvest and appetite suppression. The development pipeline is fuelled by its proprietary OptiScreen® and OptiBiotic® platform technologies designed to identify metabolic pathways and compounds that impact on human physiology and bring potential health benefits. These platforms are applicable across a wider range of other human diseases.
OptiBiotix Health secures significant exclusive licence agreement for OptiBiome
Stephen O'Hara | 01 Apr 2020